DK1296705T3 - Beta-amyloid-oligomerer til anvendelse til behandling, lindring eller forebyggelse af Alzheimers sygdom - Google Patents

Beta-amyloid-oligomerer til anvendelse til behandling, lindring eller forebyggelse af Alzheimers sygdom

Info

Publication number
DK1296705T3
DK1296705T3 DK01947033.5T DK01947033T DK1296705T3 DK 1296705 T3 DK1296705 T3 DK 1296705T3 DK 01947033 T DK01947033 T DK 01947033T DK 1296705 T3 DK1296705 T3 DK 1296705T3
Authority
DK
Denmark
Prior art keywords
alleviation
alzheimer
beta
disease
prevention
Prior art date
Application number
DK01947033.5T
Other languages
English (en)
Inventor
Ashley Bush
Robert Cherny
Rudolph Emile Tanzi
Original Assignee
Prana Biotechnology Ltd
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prana Biotechnology Ltd, Gen Hospital Corp filed Critical Prana Biotechnology Ltd
Application granted granted Critical
Publication of DK1296705T3 publication Critical patent/DK1296705T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0007Nervous system antigens; Prions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6081Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
DK01947033.5T 2000-06-28 2001-06-28 Beta-amyloid-oligomerer til anvendelse til behandling, lindring eller forebyggelse af Alzheimers sygdom DK1296705T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21477900P 2000-06-28 2000-06-28
US24217700P 2000-10-23 2000-10-23
PCT/AU2001/000786 WO2002000245A1 (en) 2000-06-28 2001-06-28 Neurotoxic oligomers

Publications (1)

Publication Number Publication Date
DK1296705T3 true DK1296705T3 (da) 2012-09-17

Family

ID=26909346

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01947033.5T DK1296705T3 (da) 2000-06-28 2001-06-28 Beta-amyloid-oligomerer til anvendelse til behandling, lindring eller forebyggelse af Alzheimers sygdom

Country Status (10)

Country Link
US (2) US7618634B2 (da)
EP (1) EP1296705B1 (da)
JP (1) JP2004501204A (da)
CN (2) CN1450908A (da)
AU (2) AU6882801A (da)
CA (1) CA2413354C (da)
DK (1) DK1296705T3 (da)
ES (1) ES2389811T3 (da)
NZ (1) NZ523428A (da)
WO (1) WO2002000245A1 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2006014638A2 (en) * 2004-07-19 2006-02-09 The General Hospital Corporation ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS
WO2006110621A2 (en) * 2005-04-11 2006-10-19 Cornell Research Foundation, Inc. Multiplexed biomarkers for monitoring the alzheimer's disease state of a subject
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
CA2635531C (en) 2005-12-29 2014-06-17 Lexicon Pharmaceutical Inc. Multicyclic amino acid derivatives and methods of their use
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) * 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US20090246191A1 (en) * 2007-10-11 2009-10-01 University Of Tennessee Research Foundation Preparation of Purified Covalently Cross-linked Abeta Oligomers and Uses Thereof
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
CA2779565A1 (en) * 2009-11-24 2011-06-03 Probiodrug Ag Novel diagnostic method for the diagnosis of alzheimer's disease or mild cognitive impairment
US20130084245A1 (en) 2010-02-25 2013-04-04 Wyeth Llc Pet monitoring of a-beta-directed immunotherapy
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2019221838A1 (en) * 2018-05-15 2019-11-21 Bausch & Lomb Incorporated Water extractable ophthalmic devices
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
DE102019129221B4 (de) * 2019-10-29 2022-05-12 Chiracon Gmbh Verfahren zur Synthese von DOPA mit einer fotolabilen Schutzgruppe und Zwischenprodukten zu dessen Herstellung
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
KR20230128606A (ko) * 2022-02-28 2023-09-05 경상국립대학교산학협력단 티로신을 유효성분으로 함유하는 알츠하이머병의 예방, 개선 또는 치료용 조성물
CN117024554A (zh) * 2023-05-30 2023-11-10 中国人民解放军空军军医大学 一种Aβ1-42寡聚体存储液的制备方法及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863735A (en) * 1985-02-19 1989-09-05 Massachusetts Institute Of Technology Biodegradable polymeric drug delivery system with adjuvant activity
US5688651A (en) * 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease

Also Published As

Publication number Publication date
AU2001268828C1 (en) 2006-12-14
CA2413354A1 (en) 2002-01-03
US20090297538A1 (en) 2009-12-03
CN101411876B (zh) 2013-01-16
NZ523428A (en) 2008-03-28
HK1131745A1 (en) 2010-02-05
US7618634B2 (en) 2009-11-17
CA2413354C (en) 2014-04-01
EP1296705B1 (en) 2012-06-13
US20040013680A1 (en) 2004-01-22
EP1296705A1 (en) 2003-04-02
US8318171B2 (en) 2012-11-27
ES2389811T3 (es) 2012-10-31
EP1296705A4 (en) 2005-04-20
WO2002000245A1 (en) 2002-01-03
AU2001268828B2 (en) 2006-07-06
AU6882801A (en) 2002-01-08
JP2004501204A (ja) 2004-01-15
CN101411876A (zh) 2009-04-22
CN1450908A (zh) 2003-10-22

Similar Documents

Publication Publication Date Title
DK1296705T3 (da) Beta-amyloid-oligomerer til anvendelse til behandling, lindring eller forebyggelse af Alzheimers sygdom
DK1392287T3 (da) Anvendelse af substituerede azetidinonderivater i behandlingen af Alzheimers sygdom
ZA200300712B (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and Behcet's syndrome.
IS6560A (is) Lyfjasamsetning fyrir meðhöndlun á bráðum, þrálátum sársauka og/eða taugakerfissársauka og mígreni
ATE296634T1 (de) (s,s)-reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen
DK1063990T3 (da) Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser
DK1594833T3 (da) 1-phenylalkancarboxylsyrederivater til behandling af neurodegenerative sygdomme
DE60132851D1 (de) Arzneimittel zur Vorbeugung, Erleichterung oder Behandlung von Hypertension
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
IS6378A (is) Efnasambönd og samsetningar gegn dvergveirum, notkun þeirra til lyfjagerðar og efni til að framleiða þau
DK1265577T3 (da) Medicinsk eller dentalmedicinsk behandlingsstol
NO20020156L (no) Titanavledede forbindelser, fremstilling og anvendelse derav
AU2002212471A1 (en) Peptides for use in the treatment of alzheimer's disease
FR2805456B1 (fr) Prothese totale de genou, du type dit "postero-stabilisee"
NO20040659L (no) Isoksazolopyridinoner og andvendelse derav ved behandling av Parkinsons sykdom
FR2810540B1 (fr) Nouvelles preparations cosmetiques ou hygieniques sous forme de dispersion
NO20032597L (no) Anvendelse av SARP-1 for behandlingen og/eller forebyggingen av skleroderma
NO20024746L (no) Anvendelse av galantamin ved behandling av nevropsykiatrisk oppförsel assosiert med Alzheimers sykdom
ITRM20000556A0 (it) S-adenosilmetionina e suoi derivati per il trattamento e la prevenzione della malattia di alzheimer.
ATE314064T1 (de) L-acetylcarnitin und l-propionylcarnitin zusammensetzung zur verhütung und behandlung von nierenstörungen und nierenenkrankheit
IL150527A0 (en) Use of vitamin d-derivatives in the treatment of osteoporosis and related bone disorders, as well as novel vitamin d3-derivatives
FR2800285B1 (fr) Technologie medicale
ITRM20000106A0 (it) Composizione per la prevenzione e/o il trattamento di vascolopatie, che comprende propionil l-carnitina e coenzima q10.
DK1152762T3 (da) Anvendelse af desoxypeganin til behandling af Alzheimers demens
ES1047413Y (es) Bolsa protectora de racimos de uva en la propia cepa.